Translational Development Acquisition (TDACW) Cash from Financing Activities (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Cash from Financing Activities for 3 consecutive years, with -$27.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities changed N/A year-over-year to -$27.2 million; the trailing twelve-month figure through Jun 2026 stood at $148.4 million (changed N/A YoY), and the FY2025 full-year result was $200000.0, down 99.89% from the prior year.
• Cash from Financing Activities fell to -$27.2 million in Q2 2026 per TDACW's latest filing, from $300000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $175.3 million in Q4 2024 and bottomed at -$27.2 million in Q2 2026.
• Historically, Cash from Financing Activities has averaged $29.7 million across 3 years, with a median of $192500.0 in 2024.
• The widest YoY moves for Cash from Financing Activities: up 99.94% in 2025, down 99.94% in 2025.
• Over 3 years, Cash from Financing Activities stood at $175.3 million in 2024, then slumped by 99.94% to $100000.0 in 2025, then plunged by 27317.43% to -$27.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$27.2 million, $300000.0, and $100000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.